8-K: NextCure Reports 2025 Results, Eyes Key ADC Data in Q2 2026

NextCure, Inc. announced its full year 2025 financial results and provided updates on its clinical-stage antibody-drug conjugate programs, SIM0505 and LNCB74, with key data readouts anticipated in 2026.

Summary

• NextCure reported a net loss of $55.8 million for the full year ended December 31, 2025, a slight increase from $55.7 million in 2024.
• Cash, cash equivalents, and marketable securities decreased to $41.8 million as of December 31, 2025, from $68.6 million at the end of 2024.
• Research and development expenses increased to $44.9 million in 2025 from $41.5 million in 2024, primarily due to $18.5 million in license fees and milestone payments for SIM0505.
• General and administrative expenses decreased to $12.7 million in 2025 from $15.7 million in 2024, mainly due to lower personnel costs.
• The company expects its current financial resources to fund operations into the first half of 2027, through proof-of-concept for SIM0505.
• Phase 1 dose escalation data for SIM0505 (CDH6 ADC) is expected in the second quarter of 2026, with initiation of the Phase 1 dose optimization study in ovarian cancer also anticipated in Q2 2026.
• NextCure plans to double U.S. trial sites and expand SIM0505 study sites into Canada and Europe in the second half of 2026, with further additions in 2027.
• An update for the LNCB74 (B7-H4 ADC) Phase 1 dose escalation trial is planned for the second half of 2026, following the initiation of higher dose cohort enrollment in November 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While the company continues to incur losses and burn cash, this is expected for a clinical-stage biopharma. The significant progress on the SIM0505 program, including upcoming data readouts and planned trial expansion, coupled with a funding runway into H1 2027, provides clear catalysts and financial stability for the near term.

Positives

• Anticipated data readout for SIM0505 Phase 1 dose escalation study in Q2 2026, a significant clinical milestone.
• Initiation of SIM0505 Phase 1 dose optimization study in ovarian cancer expected in Q2 2026, accelerating development in a key indication.
• Plans to double U.S. trial sites and expand SIM0505 into Canada and Europe in H2 2026, indicating aggressive program advancement.
• Current financial resources are expected to fund operations into the first half of 2027, providing a runway through SIM0505 proof-of-concept.
• General and administrative expenses decreased by $3.0 million year-over-year, reflecting cost management.

Negatives

• Cash, cash equivalents, and marketable securities decreased by $26.8 million from $68.6 million in 2024 to $41.8 million in 2025.
• Net loss slightly increased to $55.8 million in 2025 from $55.7 million in 2024.
• Research and development expenses increased by $3.4 million, driven by $18.5 million in license fees and milestone payments for SIM0505, contributing to the overall net loss.

Risks

• Positive results in preclinical studies may not be predictive of the results of clinical trials.
• Limited operating history and no products approved for commercial sale.
• History of significant losses.
• Need and ability to obtain additional financing on acceptable terms or at all.
• Risks related to clinical development, marketing approval, and commercialization.
• Reliance upon collaborators and international vendors for advancing clinical programs.
• Ability to maintain listing of common stock on the Nasdaq Global Select Market.
• Dependence on key personnel.

Future Outlook

NextCure anticipates 2026 to be a transformational year, with key clinical dose escalation data from the Phase 1 trial for SIM0505 expected in Q2 2026. The company also expects to initiate the Phase 1 dose optimization study for SIM0505 in ovarian cancer in Q2 2026 and plans to significantly expand trial sites for this program. A trial update for LNCB74 is planned for the second half of 2026. Current financial resources are projected to fund operations into the first half of 2027, supporting the SIM0505 program through proof-of-concept.

Management Comments

• Michael Richman, President and CEO, stated that '2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505, in development for multiple cancers.'
• Richman also noted that 'Since acquiring the program in June of 2025, we have made rapid clinical and regulatory progress and soon expect to begin enrolling platinum resistant ovarian cancer patients in the Phase 1 dose optimization study.'
• Richman added that 'To accelerate the program, we plan to double the number of U.S. trial sites and expand our footprint into multiple other countries.'

Industry Context

StockSavvy.ai notes that NextCure's focus on antibody-drug conjugates (ADCs) like SIM0505 and LNCB74 aligns with a significant trend in oncology, where ADCs are gaining traction as a promising class of targeted therapies. The emphasis on CDH6 and B7-H4 targets positions NextCure in competitive areas, particularly in ovarian and breast cancers. The rapid progression of SIM0505 into dose optimization and planned site expansion indicates an aggressive development strategy, which is common for biopharmaceutical companies aiming to accelerate novel therapies to market. The financial results reflect the typical investment phase of a clinical-stage company, with increased R&D spending for pipeline advancement.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trial data for SIM0505 and LNCB74 are positive, but continued dilution risk from future capital raises given ongoing losses. The private placement in November 2025 already contributed to dilution.
• Patients: Potential for new treatment options, especially for advanced solid tumors and platinum-resistant ovarian cancer, if the ADC programs prove safe and effective.
• Employees: Continued employment and potential growth opportunities as clinical programs advance and trial sites expand.
• Creditors: No specific impact mentioned, but the company's cash runway into H1 2027 provides some financial stability.

Next Steps

• Present Phase 1 dose escalation data for SIM0505 in Q2 2026.
• Initiate Phase 1 dose optimization study for SIM0505 in ovarian cancer in Q2 2026.
• Double the number of U.S. trial sites for SIM0505 in H2 2026.
• Expand SIM0505 trial footprint into Canada and Europe in H2 2026.
• Continue study site additions for SIM0505 in 2027.
• Provide a trial update for LNCB74 in H2 2026.

Key Dates

Recommendation

The company is at a critical juncture with key clinical data readouts for SIM0505 expected in Q2 2026. While the financial position provides a runway into H1 2027, the stock's performance will heavily depend on the upcoming clinical trial results. Investors should hold and await these catalysts before making further investment decisions, as positive data could significantly boost the stock, while negative data could lead to substantial declines.

Keywords

NextCure, NXTC, Biopharmaceutical, Cancer Therapy, Antibody-Drug Conjugate, ADC, SIM0505, CDH6 ADC, Ovarian Cancer, Platinum Resistant Ovarian Cancer, LNCB74, B7-H4 ADC, Clinical Trials, Phase 1, Financial Results, R&D Expenses, Net Loss, Cash Position